放射性标记的反向激动剂与大麻素 CB1 受体的结合在精神分裂症患者中增加。
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.
机构信息
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1003, USA.
出版信息
Schizophr Res. 2012 Nov;141(2-3):185-8. doi: 10.1016/j.schres.2012.07.021. Epub 2012 Aug 19.
Abstract
This study sought to determine whether cannabinoid-1 (CB(1)) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB(1) receptor inverse agonist radioligand [(3)H]MePPEP was used to measure specific binding to CB(1) receptors. The specific binding of [(3)H]MePPEP to CB(1) receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [(18)F]FMPEP-d(2) (80% statistical power, p<0.05).
摘要
这项研究旨在确定与对照组（n=43）相比，精神分裂症患者（精神分裂症；n=47）死后背外侧前额叶皮质（DLPFC）中的大麻素-1（CB(1)）受体结合是否发生改变。使用大麻素-1（CB(1)）受体反向激动剂放射性配体 [(3)H]MePPEP 来测量 CB(1)受体的特异性结合。与对照组相比，精神分裂症患者的 [(3)H]MePPEP 与 CB(1)受体的特异性结合高 20%。功效分析表明，每组需要 53 个受试者，才能使用正电子发射断层扫描（PET）和结构上相关的反向激动剂放射性配体 [(18)F]FMPEP-d(2) 检测到类似的差异（80%的统计功效，p<0.05）。
相似文献
1
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.
Schizophr Res. 2012 Nov;141(2-3):185-8. doi: 10.1016/j.schres.2012.07.021. Epub 2012 Aug 19.
2
Pharmacological characterization of the cannabinoid CB₁ receptor PET ligand ortholog, [³H]MePPEP.
Eur J Pharmacol. 2010 Dec 15;649(1-3):44-50. doi: 10.1016/j.ejphar.2010.08.055. Epub 2010 Sep 17.
3
Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia.
Schizophr Res. 2014 Oct;159(1):124-9. doi: 10.1016/j.schres.2014.07.017. Epub 2014 Aug 5.
4
Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.
Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1499-506. doi: 10.1007/s00259-010-1411-7. Epub 2010 Mar 24.
5
Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.
J Nucl Med. 2010 Jan;51(1):112-20. doi: 10.2967/jnumed.109.067074. Epub 2009 Dec 15.
6
Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.
Neuroimage. 2008 Jul 1;41(3):690-8. doi: 10.1016/j.neuroimage.2008.03.004. Epub 2008 Mar 18.
7
The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.
Neuropsychopharmacology. 2008 Jan;33(2):259-69. doi: 10.1038/sj.npp.1301402. Epub 2007 Mar 28.
8
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.
Neuroimage. 2010 Oct 1;52(4):1505-13. doi: 10.1016/j.neuroimage.2010.04.034. Epub 2010 Apr 18.
9
Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.
Neuropsychopharmacology. 2011 Jul;36(8):1620-30. doi: 10.1038/npp.2011.43. Epub 2011 Apr 6.
10
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand.
Neuroimage. 2009 Nov 1;48(2):362-70. doi: 10.1016/j.neuroimage.2009.06.059. Epub 2009 Jun 30.
引用本文的文献
1
analyses of the involvement of GPR55, CB1R and TRPV1: response to THC, contribution to temporal lobe epilepsy, structural modeling and updated evolution.
Front Neuroinform. 2024 Feb 7;18:1294939. doi: 10.3389/fninf.2024.1294939. eCollection 2024.
2
Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study.
Neurobiol Dis. 2023 Sep;185:106262. doi: 10.1016/j.nbd.2023.106262. Epub 2023 Aug 15.
3
Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study.
bioRxiv. 2023 Apr 11:2023.04.11.536217. doi: 10.1101/2023.04.11.536217.
4
Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB receptor density in cell membranes: an alternative to radioligand binding methods.
Microb Cell Fact. 2022 Sep 15;21(1):192. doi: 10.1186/s12934-022-01914-1.
5
Cannabinoids, reward processing, and psychosis.
Psychopharmacology (Berl). 2022 May;239(5):1157-1177. doi: 10.1007/s00213-021-05801-2. Epub 2021 Mar 1.
6
Endocannabinoid system in psychotic and mood disorders, a review of human studies.
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110096. doi: 10.1016/j.pnpbp.2020.110096. Epub 2020 Sep 6.
7
Endocannabinoid System Components as Potential Biomarkers in Psychiatry.
Front Psychiatry. 2020 Apr 27;11:315. doi: 10.3389/fpsyt.2020.00315. eCollection 2020.
8
Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.
Schizophr Bull. 2020 Dec 1;46(6):1547-1557. doi: 10.1093/schbul/sbaa038.
9
Effects of combined 5-HT and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.
Psychopharmacology (Berl). 2020 Jun;237(6):1643-1655. doi: 10.1007/s00213-020-05485-0. Epub 2020 Feb 24.
10
Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.
Brain Sci. 2020 Feb 12;10(2):97. doi: 10.3390/brainsci10020097.
本文引用的文献
1
Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.
Neuropsychopharmacology. 2011 Jul;36(8):1620-30. doi: 10.1038/npp.2011.43. Epub 2011 Apr 6.
2
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.
Neuropsychopharmacology. 2010 Sep;35(10):2060-71. doi: 10.1038/npp.2010.75. Epub 2010 Jun 16.
3
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.
Neuroimage. 2010 Oct 1;52(4):1505-13. doi: 10.1016/j.neuroimage.2010.04.034. Epub 2010 Apr 18.
4
Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.
Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1499-506. doi: 10.1007/s00259-010-1411-7. Epub 2010 Mar 24.
5
Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.
Psychopharmacology (Berl). 2009 Oct;206(2):313-24. doi: 10.1007/s00213-009-1608-2. Epub 2009 Aug 4.
6
A flexible and accurate genotype imputation method for the next generation of genome-wide association studies.
PLoS Genet. 2009 Jun;5(6):e1000529. doi: 10.1371/journal.pgen.1000529. Epub 2009 Jun 19.
7
Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.
J Med Chem. 2008 Sep 25;51(18):5833-42. doi: 10.1021/jm800416m.
8
The incentive salience of alcohol: translating the effects of genetic variant in CNR1.
Arch Gen Psychiatry. 2008 Jul;65(7):841-50. doi: 10.1001/archpsyc.65.7.841.
9
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.
Arch Gen Psychiatry. 2008 Jul;65(7):772-84. doi: 10.1001/archpsyc.65.7.772.
10
No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.
Neurosci Bull. 2007 Nov;23(6):341-7. doi: 10.1007/s12264-007-0051-9.
Zotero 插件